Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-789: Pembrolizumab + Chemo in EGFR-mutated NSCLC
NCT03515837Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2018
- Primary completion
- Jan 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 17
01
Overview
A Phase 3 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Jun 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03515837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03515837.